The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index; 48 of the 102 sources its claims cite were checked for support.
Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review
Open accessAbstract
Systematic review of treatment in adolescents with ADHD and SUD, including review of longitudinal medication-SUD links.
Overview
CoChat Summary
TL;DR
This systematic review found that evidence for treating adolescents with concurrent ADHD and substance use disorder (SUD) is very limited, and no pharmacological trial showed a robust between-group effect on either ADHD or SUD. In contrast, ADHD medications showed moderate-to-large benefits for ADHD symptoms in adolescents without SUD, while psychosocial and complementary approaches lacked strong evidence in either group.
Key findings
- The review included 4 placebo-controlled pharmacological trials in adolescents with concurrent ADHD and SUD (458 enrolled patients) and 12 placebo-controlled pharmacological trials in adolescents with ADHD without SUD (2675 patients).
- In the comorbid ADHD+SUD trial by Riggs et al. (2011), 303 adolescents received OROS-methylphenidate or placebo plus weekly CBT/MI for SUD; both groups improved on self-reported ADHD symptoms and substance-use days, but no between-group difference was found on the primary outcomes.
- Across the four pharmacological trials in adolescents with ADHD and SUD, the evidence base was less than 500 patients and none showed a robust treatment effect on ADHD or SUD.
- In adolescents with ADHD without SUD, the review reports significant ADHD symptom improvements with active medication, with effect sizes in the moderate-to-large range: MPH d = 0.53–1.33, LDX d = 0.80–1.23, MAS-XR d = 0.80, pemoline d = 2.05, atomoxetine d = 0.99, and guanfacine d = 0.52.
- For childhood ADHD and later SUD, the review reports increased later SUD risk in meta-analyses with mean odds ratios ranging from 1.34 to 3.48, and one prospective study found a hazard ratio of 1.77 versus healthy controls; some longitudinal studies suggested stimulant treatment may be protective, including a 31% lower rate of substance-related events in one registry study and a 14% to 19% reduction in odds of SUD-related emergency visits in another.
Methods
- Systematic review of studies published 2000 to 11 April 2021, searching Medline, PsycINFO, and the Cochrane Database of Systematic Reviews, plus reference lists.
- Included original English-language controlled studies and meta-analyses on ADHD treatment in adolescents 12–20 years old, with ADHD diagnosed by DSM-IV/-5 or ICD-10/-11 criteria; studies had to report validated ADHD outcomes and, for comorbid SUD, quantitative substance-use outcomes.
- Study selection and data extraction were done by review authors on full texts, with risk of bias assessed using Cochrane RoB-2 and evidence quality rated with the SIGN grading system.
Limitations
- The paper states that the evidence for adolescents with concurrent ADHD and SUD is limited, does not support strong recommendations, and that more research is needed.
- For psychosocial treatment, the paper says there were no randomized trials or meta-analyses in youth with concurrent ADHD and SUD, and for complementary interventions in that group, research was absent.
- Evident from the text: many included studies had high risk of bias, short follow-up, substantial between-study heterogeneity, and in some cases small samples or no separate adolescent outcomes; the paper also notes that some conclusions about long-term effects cannot be firm because extension studies were open-label and involved only selected participants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Valid · 4 Not valid · 19 Not checked · 58 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Adverse pharmacological interactions between the study medication and the adolescent’s substance use at the same day were only reported in the trial of Riggs et al. (2011) [37], and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, respectively.”
§ Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review > 3. Results > 3.2. Pharmacological Interventions
What the sources say
- Partly supportedcites [37] Riggs, 2011, Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders, J. Am. Acad. Child Adolesc. Psychiatry sourceExperimental — accuracy not yet measured
The Results section (Medication Tolerability, Safety, Adverse Events) gives the stated counts and percentages for OROS-MPH and placebo, but describes the interactions as *possible* adverse interactions reported by participants, not established pharmacological interactions. This paper also cannot establish the citing document’s cross-trial assertion that such interactions were reported only in Riggs et al. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, symptoms of ADHD and their consequences may increase the risk of addiction problems, particularly in those with co-occurring oppositional defiant disorder and conduct disorder [1,12].”
§ Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review > 1. Introduction
What the sources say
- Supportedcites [1] Lee, 2011, Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review, Clin. Psychol. Rev. source
The Results section on comorbid disruptive behavior disorders reports higher rates of substance use disorders among children with ADHD plus ODD/CD than among those with ADHD alone. The Discussion also reports a prospective association between childhood ADHD and later substance problems while noting that the mechanisms remain uncertain, consistent with the claim’s hedged wording. Page numbers are not available in the supplied passages. (LLM, conf=0.90)
- Supportedcites [12] Molina, 2014, Attention-deficit/hyperactivity disorder and risk of substance use disorder: Developmental considerations, potential pathways, and opportunities for research, Annu. Rev. Clin. Psychol. source
The ‘Role of Conduct Disorder in ADHD Risk of SUD’ section describes a possible pathway from ADHD-related impulsivity and escalating conduct problems to problematic substance use, and identifies later CD as a potentially crucial comorbidity. The ‘Depression, Other Negative Affect (Impulsive Anger), and SUD’ section also describes ODD as highly comorbid with ADHD and predictive of substance use disorder. Together, these passages support the claim’s hedged wording; no page numbers are available in our copy. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“found no between-group difference in improvement for neither ADHD or substance use, both based on self-report and urinalysis [39].”
§ Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review > 3. Results > 3.2. Pharmacological Interventions
What the sources say
- Supportedcites [39] Thurstone, 2010, Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder, J. Am. Acad. Child Adolesc. Psychiatry source
The Results and Discussion report no significant between-group difference in ADHD or substance-use change. The Methods identify adolescent self-report as the primary measure for both outcomes, and the Results also report no between-group difference in negative urine drug screens. The trial compared atomoxetine plus MI/CBT with placebo plus MI/CBT. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Studies suggest that the co-occurrence of ADHD and SUD can be partly explained by common vulnerability factors, including genetic predispositions [7,8,9]”
§ Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [7] Derks, 2014, Genetic and environmental influences on the relationship between adult ADHD symptoms and self-reported problem drinking in 6024 Dutch twins, Psychol. Med. source
- Not checked — no full text of the sourcecites [8] Vink, 2018, Relating addiction and psychiatric disorders, Science source
- Supportedcites [9] Abdellaoui, 2021, Genomic Relationships across Psychiatric Disorders Including Substance Use Disorders, Drug Alcohol Depend. source
Section 3.1 reports significant genetic correlations between ADHD and all three substance use disorders studied. The Discussion says shared genetic influences may help explain why substance use disorders and psychiatric disorders co-occur more often than expected by chance. Together, these passages support the claim's qualified explanation. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In five of the six trials with a non-active control condition (waiting-list control group), participants in the intervention group showed stronger post-treatment improvements in ADHD-symptoms compared with participants in the control group [62,63,64,65,73,74].”
§ Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review > 3. Results > 3.4. Psychosocial Interventions
What the sources say
- Not checked — no full text of the sourcecites [62] Evans, 2007, Cumulative benefits of secondary school-based treatment of students with attention deficit hyperactivity disorder, Sch. Psychol. Rev. source
- Not checked — no full text of the sourcecites [63] Evans, 2016, Evaluation of a school-based treatment program for young adolescents with ADHD, J. Consult. Clin. Psychol. source
- Partly supportedcites [64] Langberg, 2012, Evaluation of the homework, organization, and planning skills (HOPS) intervention for middle school students with attention deficit hyperactivity disorder as implemented by school mental health providers, Sch. Psychol. Rev. sourceExperimental — accuracy not yet measured
The Results (Outcomes; page unavailable) report that HOPS participants improved significantly more than the waitlist group on parent-rated inattentive symptoms. The overall ADHD-symptom group-by-time interaction was marginally non-significant (p = .059), so this trial supports the claim for inattention, not ADHD symptoms broadly. This paper alone cannot establish the aggregate count of five of six trials. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [65] Schramm, 2016, Training problem solving and organizational skills in adolescents with attention-deficit/hyperactivity disorder: A randomized controlled trial, J. Cogn. Educ. Psychol. source
- Supportedcites [73] Sprich, 2016, A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents, J. Child Psychol. Psychiatry source
The Methods describe this study as a trial comparing CBT with a wait-list control in adolescents with ADHD. The Results report greater improvement in ADHD symptom ratings after CBT. The paper supports its role as one of the cited trials; it does not itself establish the citing sentence’s count across all six trials. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [74] Vidal, 2015, Group therapy for adolescents with attention-deficit/hyperactivity disorder: A randomized controlled trial, J. Am. Acad. Child Adolesc. Psychiatry source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims · 9 with their cited sources checked
Create a free account to see all 112 claims and to verify the 3 references still open.
- It may state two separate claims as one. 51
- Probably not a substantial claim. 9
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our findings extend prior systematic review findings focusing on outcomes of interventions for adolescents with SU co-occurring with other MH problems [75–79] and reviews of interventions for trauma/SU that focused on adult populations [25, 80].”
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
A new system for grading recommendations in evidence based guidelines
Harbour, R., & Miller, J. (2001) · BMJ · doi:10.1136/bmj.323.7308.334 · Cited by 1,637
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Sex and gender differences in substance use disorders
McHugh, R. K., Votaw, V. R., Sugarman, D. E., & Greenfield, S. F. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.10.012 · Cited by 1,076
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974
Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.01.006 · Cited by 875
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity.
Armstrong, T. D., & Costello, E. J. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.70.6.1224 · Cited by 692
Erskine, H. E., Norman, R. E., Ferrari, A. J., Chan, G. C. K., Copeland, W. E., Whiteford, H. A., & Scott, J. G. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.06.016 · Cited by 555
Cited by
Köck, P., Meyer, M., Elsner, J., Dürsteler, K. M., Vogel, M., & Walter, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.827658 · Cited by 43
Becker, T. D., Castañeda Ramirez, S., Bruges Boude, A., Leong, A., Ivanov, I., & Rice, T. R. (2024) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02265-x · Cited by 18
Weiss, F., Tidona, S., Carli, M., Perugi, G., & Scarselli, M. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220830154002 · Cited by 13
Molinero, K., & Hinckley, J. D. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.07.003 · Cited by 8
Rasheed, A. H. E., Moneam, M. H. A. E., Tawfik, F. A., Farid, R. W. M., & Elrassas, H. H. (2023) · Middle East Current Psychiatry · doi:10.1186/s43045-023-00295-4 · Cited by 9
“A link was found between childhood ADHD and early SUD in youth and young adults [4, 5], in which it could persist and affect between 35 and 80% in their adulthood [6–8].”
Background
Metadata
- Authors
- Özgen, H., Spijkerman, R., Noack, M., Holtmann, M., Schellekens, A., Dalsgaard, S., van den Brink, W., & Hendriks, V.
- Affiliations
- Parnassia Addiction Research Centre (PARC), Parnassia Psychiatric Institute, 2512 HN The Hague, The Netherlands
- Parnassia Groep (NL)
- LWL-Universitätsklinik Hamm (DE)
- Radboud University Nijmegen (NL)
- Aarhus University (DK)
- International Collaboration on ADHD and Substance Abuse (ICASA) Foundation, 6500 HE Nijmegen, The Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-08-30
- Volume
- 10
- Issue
- 17
- Pages
- 3908
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8432200
- OpenAlex
- W3197422577
- Cited by
- 27
- References
- 90
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 1
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Keywords
- attention deficit hyperactivity disorder, substance use disorders, comorbidities, adolescents, stimulant pharmacotherapy, cognitive behavioral therapy, psychosocial interventions, complementary therapy, childhood ADHD, substance use prevention, treatment effectiveness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. https://app.cochat.ai/papers/10.3390/jcm10173908
- The paper
- Özgen, H., Spijkerman, R., Noack, M., Holtmann, M., Schellekens, A., Dalsgaard, S., van den Brink, W., & Hendriks, V. (2021). Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10173908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
